Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.